Russell MD, Yates M, Bechman K, Rutherford AI, Subesinghe S, Lanyon P, et al. Rising Incidence of Acute Hospital Admissions due to Gout. J Rheumatol. 2020;47:619–23.

Article  PubMed  CAS  Google Scholar 

Xia Y, Wu Q, Wang H, Zhang S, Jiang Y, Gong T, et al. Global, regional and national burden of gout, 1990–2017: a systematic analysis of the Global Burden of Disease Study. Rheumatology. 2020;59:1529–38.

Article  PubMed  CAS  Google Scholar 

Dalbeth N, Stamp LK, Merriman TR. The genetics of gout: towards personalised medicine? BMC Med. 2017;15:108.

Article  PubMed  PubMed Central  Google Scholar 

Punzi L, Scanu A, Galozzi P, Luisetto R, Spinella P, Scirè CA, et al. One year in review 2020: gout. Clin Exp Rheumatol. 2020;38:807–21.

PubMed  Google Scholar 

Disveld IJM, Zoakman S, Jansen TLTA, Rongen GA, Kienhorst LBE, Janssens HJEM, et al. Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study. Clin Rheumatol. Springer Science and Business Media LLC; 2019;38:1385–91.

Vedder D, Gerritsen M, Duvvuri B, van Vollenhoven RF, Nurmohamed MT, Lood C. Neutrophil activation identifies patients with active polyarticular gout. Arthritis Res Ther. Springer Science and Business Media LLC; 2020;22:148.

Stamp L, Dalbeth N. Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution. Semin Arthritis Rheum. 2017;46:457–64.

Article  PubMed  Google Scholar 

Kuo C-F, Grainge MJ, See L-C, Yu K-H, Luo S-F, Zhang W, et al. Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther. 2015;17:13.

Article  PubMed  PubMed Central  Google Scholar 

Pascart T, Norberciak L, Ea H-K, Guggenbuhl P, Lioté F. Patients with early-onset gout and development of earlier severe joint involvement and metabolic comorbid conditions: Results from a cross-sectional epidemiologic survey. Arthritis Care Res. 2019;71:986–92.

Article  Google Scholar 

Zhang B, Fang W, Zeng X, Zhang Y, Ma Y, Sheng F, et al. Clinical characteristics of early- and late-onset gout: A cross-sectional observational study from a Chinese gout clinic. Medicine. 2016;95:e5425.

Article  PubMed  PubMed Central  Google Scholar 

Major TJ, Dalbeth N, Stahl EA, Merriman TR. An update on the genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2018;14:341–53.

Article  PubMed  CAS  Google Scholar 

Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Ho Cha S, et al. Molecular identification of a renal urate–anion exchanger that regulates blood urate levels. Nature. 2002;417:447–52.

Article  PubMed  CAS  Google Scholar 

Matsuo H, Chiba T, Nagamori S, Nakayama A, Domoto H, Phetdee K, et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet. 2008;83:744–51.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CNA, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet. 2008;40:437–42.

Article  PubMed  CAS  Google Scholar 

Woodward OM, Köttgen A, Coresh J, Boerwinkle E, Guggino WB, Köttgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. Proceedings of the National Academy of Sciences; 2009;106:10338–42.

Abhishek A, Courtney P, Jenkins W, Sandoval-Plata G, Jones AC, Zhang W, et al. Brief report: Monosodium urate monohydrate crystal deposits are common in asymptomatic sons of patients with gout: The sons of gout study. Arthritis rheumatol Wiley. 2018;70:1847–52.

Article  CAS  Google Scholar 

Dalbeth N, House ME, Aati O, Tan P, Franklin C, Horne A, et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Ann Rheum Dis BMJ. 2015;74:908–11.

Article  Google Scholar 

Son M, Seo J, Yang S. Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016–2017. PLoS ONE. 2020;15:e0228684.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liang J, Jiang Y, Huang Y, Song W, Li X, Huang Y, et al. The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study. Lipids Health Dis. 2020;19:31.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Choi HG, Kwon B-C, Kwon MJ, Kim JH, Kim J-H, Park B, et al. Association between Gout and Dyslipidemia: A Nested Case-Control Study Using a National Health Screening Cohort. J Pers Med. 2022;12.

Yang F, Liu M, Qin N, Li S, Yu M, Wang C, et al. Lipidomics coupled with pathway analysis characterizes serum metabolic changes in response to potassium oxonate induced hyperuricemic rats. Lipids Health Dis. 2019;18:112.

Article  PubMed  PubMed Central  Google Scholar 

Liu S, Wang Y, Liu H, Xu T, Wang M-J, Lu J, et al. Serum lipidomics reveals distinct metabolic profiles for asymptomatic hyperuricemic and gout patients. Rheumatology (Oxford). 2022;61:2644–51.

Article  PubMed  CAS  Google Scholar 

Wang C, Lu J, Sun W, Merriman TR, Dalbeth N, Wang Z, et al. Profiling of serum oxylipins identifies distinct spectrums and potential biomarkers in young people with very early onset gout. Rheumatology. Oxford University Press (OUP); 2022.

Choi Y-J, Shin H-S, Choi HS, Park J-W, Jo I, Oh E-S, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Invest. 2014;94:1114–25.

Article  PubMed  CAS  Google Scholar 

Liu N, Sun Q, Xu H, Yu X, Chen W, Wei H, et al. Hyperuricemia induces lipid disturbances mediated by LPCAT3 upregulation in the liver. FASEB J. 2020;34:13474–93.

Article  PubMed  CAS  Google Scholar 

Neogi T, Jansen TLTA, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74:1789–98.

Article  PubMed  CAS  Google Scholar 

Sarafian MH, Gaudin M, Lewis MR, Martin F-P, Holmes E, Nicholson JK, et al. Objective set of criteria for optimization of sample preparation procedures for ultra-high throughput untargeted blood plasma lipid profiling by ultra performance liquid chromatography-mass spectrometry. Anal Chem. 2014;86:5766–74.

Article  PubMed  CAS  Google Scholar 

Xuan Q, Hu C, Yu D, Wang L, Zhou Y, Zhao X, et al. Development of a High Coverage Pseudotargeted Lipidomics Method Based on Ultra-High Performance Liquid Chromatography-Mass Spectrometry. Anal Chem. 2018;90:7608–16.

Article  PubMed  PubMed Central  CAS  Google Scholar 

AlzbetaG. AlzbetaG/Metabol: First version. 2019 [cited 2022 Dec 13]; Available from: https://zenodo.org/record/3235775

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469–80.

Toyoda Y, Pavelcová K, Bohatá J, Ješina P, Kubota Y, Suzuki H, et al. Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout. Int J Mol Sci [Internet]. 2021;22. Available from: https://doi.org/10.3390/ijms22041935

Toyoda Y, Pavelcová K, Klein M, Suzuki H, Takada T, Stiburkova B. Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2. Arthritis Res Ther. 2019;21:219.

Article  PubMed  PubMed Central  Google Scholar 

Toyoda Y, Mančíková A, Krylov V, Morimoto K, Pavelcová K, Bohatá J, et al. Functional Characterization of Clinically-Relevant Rare Variants in Identified in a Gout and Hyperuricemia Cohort. Cells. 2019;8.

Pavelcova K, Bohata J, Pavlikova M, Bubenikova E, Pavelka K, Stiburkova B. Evaluation of the Influence of Genetic Variants of SLC2A9 (GLUT9) and SLC22A12 (URAT1) on the Development of Hyperuricemia and Gout. J Clin Med Res. Multidisciplinary Digital Publishing Institute; 2020;9:2510.

Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007;27:435–40.

Kazachkov M, Chen Q, Wang L, Zou J. Substrate preferences of a lysophosphatidylcholine acyltransferase highlight its role in phospholipid remodeling. Lipids. 2008;43:895–902.

Article  PubMed  CAS  Google Scholar 

Shao G, Qian Y, Lu L, Liu Y, Wu T, Ji G, et al. Research progress in the role and mechanism of LPCAT3 in metabolic related diseases and cancer. J Cancer. 2022;13:2430–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shi SY, Luk CT, Brunt JJ, Sivasubramaniyam T, Lu S-Y, Schroer SA, et al. Adipocyte-specific deficiency of Janus kinase (JAK) 2 in mice impairs lipolysis and increases body weight, and leads to insulin resistance with ageing. Diabetologia. 2014;57:1016–26.

Article  PubMed  CAS  Google Scholar 

Dodington DW, Desai HR, Woo M. JAK/STAT - Emerging Players in Metabolism. Trends Endocrinol Metab. 2018;29:55–65.

Article  PubMed  CAS  Google Scholar 

Shimano H. SREBPs: physiology and pathophysiology of the SREBP family. FEBS J. 2009;276:616–21.

Article  PubMed  CAS  Google Scholar 

Okazaki H, Goldstein JL, Brown MS, Liang G. LXR-SREBP-1c-phospholipid transfer protein axis controls very low density lipoprotein (VLDL) particle size. J Biol Chem Elsevier BV. 2010;285:6801–10.

Article  CAS  Google Scholar 

Rong X, Wang B, Dunham MM, Hedde PN, Wong JS, Gratton E, et al. Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion. Elife. 2015;4.

Jensen PN, Fretts AM, Yu C, Hoofnagle AN, Umans JG, Howard BV, et al. Circulating sphingolipids, fasting glucose, and impaired fasting glucose: The Strong Heart Family Study. EBioMedicine. 2019;41:44–9.

Article  PubMed  Google Scholar 

Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016;37:1967–76.

Article  PubMed  PubMed Central  CAS